{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:42:48Z","timestamp":1784288568280,"version":"3.55.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802974"],"award-info":[{"award-number":["81802974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Technology Research and Development Program of the Ministry of Science and Technology of China","award":["2014BAI04B01"],"award-info":[{"award-number":["2014BAI04B01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10014-021-00399-x","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T17:09:16Z","timestamp":1619456956000},"page":"156-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options"],"prefix":"10.1007","volume":"38","author":[{"given":"Chaoying","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-3694","authenticated-orcid":false,"given":"Wenyong","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"issue":"2","key":"399_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","volume":"14","author":"M Preusser","year":"2018","unstructured":"Preusser M, Brastianos PK, Mawrin C (2018) Advances in meningioma genetics: novel therapeutic opportunities. Nat Rev Neurol 14(2):106\u2013115. https:\/\/doi.org\/10.1038\/nrneurol.2017.168","journal-title":"Nat Rev Neurol"},{"key":"399_CR2","doi-asserted-by":"publisher","first-page":"14433","DOI":"10.1038\/ncomms14433","volume":"8","author":"AS Harmanci","year":"2017","unstructured":"Harmanci AS, Youngblood MW, Clark VE, Coskun S, Henegariu O, Duran D, Erson-Omay EZ, Kaulen LD, Lee TI, Abraham BJ, Simon M, Krischek B, Timmer M, Goldbrunner R, Omay SB, Baranoski J, Baran B, Carrion-Grant G, Bai H, Mishra-Gorur K, Schramm J, Moliterno J, Vortmeyer AO, Bilguvar K, Yasuno K, Young RA, Gunel M (2017) Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun 8:14433. https:\/\/doi.org\/10.1038\/ncomms14433","journal-title":"Nat Commun"},{"issue":"6","key":"399_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"issue":"5","key":"399_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/1097-0142(20000901)89:5<1102::AID-CNCR20>3.0.CO;2-L","volume":"89","author":"F Yamasaki","year":"2000","unstructured":"Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K (2000) Recurrence of meningiomas. Cancer 89(5):1102\u20131110","journal-title":"Cancer"},{"issue":"11","key":"399_CR5","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1634\/theoncologist.2011-0193","volume":"16","author":"S Saraf","year":"2011","unstructured":"Saraf S, McCarthy BJ, Villano JL (2011) Update on meningiomas. Oncologist 16(11):1604\u20131613. https:\/\/doi.org\/10.1634\/theoncologist.2011-0193","journal-title":"Oncologist"},{"issue":"1","key":"399_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","volume":"20","author":"D Simpson","year":"1957","unstructured":"Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1):22\u201339","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"399_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/neuonc\/not330","volume":"16","author":"T Kaley","year":"2014","unstructured":"Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol 16(6):829\u2013840. https:\/\/doi.org\/10.1093\/neuonc\/not330","journal-title":"Neuro Oncol"},{"issue":"4","key":"399_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2559.1993.tb01218.x","volume":"23","author":"CA McLean","year":"1993","unstructured":"McLean CA, Jolley D, Cukier E, Giles G, Gonzales MF (1993) Atypical and malignant meningiomas: importance of micronecrosis as a prognostic indicator. Histopathology 23(4):349\u2013353","journal-title":"Histopathology"},{"issue":"3","key":"399_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3171\/jns.1982.56.3.0317","volume":"56","author":"HG Deen Jr","year":"1982","unstructured":"Deen HG Jr, Scheithauer BW, Ebersold MJ (1982) Clinical and pathological study of meningiomas of the first two decades of life. J Neurosurg 56(3):317\u2013322. https:\/\/doi.org\/10.3171\/jns.1982.56.3.0317","journal-title":"J Neurosurg"},{"issue":"12","key":"399_CR10","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/00000478-199712000-00008","volume":"21","author":"A Perry","year":"1997","unstructured":"Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21(12):1455\u20131465","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"399_CR11","first-page":"237","volume":"5","author":"SA Rempel","year":"1999","unstructured":"Rempel SA, Ge S, Gutierrez JA (1999) SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 5(2):237\u2013241","journal-title":"Clin Cancer Res"},{"issue":"10","key":"399_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/neuonc\/nox071","volume":"19","author":"B Brokinkel","year":"2017","unstructured":"Brokinkel B, Hess K, Mawrin C (2017) Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review. Neuro Oncol 19(10):1298\u20131307. https:\/\/doi.org\/10.1093\/neuonc\/nox071","journal-title":"Neuro Oncol"},{"issue":"2","key":"399_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2990.2006.00792.x","volume":"33","author":"L Zeltner","year":"2007","unstructured":"Zeltner L, Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Kim YJ, Bornemann A (2007) The astrocytic response towards invasive meningiomas. Neuropathol Appl Neurobiol 33(2):163\u2013168. https:\/\/doi.org\/10.1111\/j.1365-2990.2006.00792.x","journal-title":"Neuropathol Appl Neurobiol"},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.wneu.2016.06.055","volume":"93","author":"DC Spille","year":"2016","unstructured":"Spille DC, Hess K, Sauerland C, Sanai N, Stummer W, Paulus W, Brokinkel B (2016) Brain invasion in meningiomas: incidence and correlations with clinical variables and prognosis. World Neurosurg 93:346\u2013354. https:\/\/doi.org\/10.1016\/j.wneu.2016.06.055","journal-title":"World Neurosurg"},{"issue":"10 Suppl","key":"399_CR15","first-page":"2386","volume":"53","author":"SA Rempel","year":"1993","unstructured":"Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosenblum ML (1993) Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Can Res 53(10 Suppl):2386\u20132392","journal-title":"Can Res"},{"issue":"3","key":"399_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11060-010-0342-2","volume":"99","author":"C Mawrin","year":"2010","unstructured":"Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99(3):379\u2013391. https:\/\/doi.org\/10.1007\/s11060-010-0342-2","journal-title":"J Neurooncol"},{"issue":"4","key":"399_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1227\/NEU.0000000000000461","volume":"75","author":"SQ Sun","year":"2014","unstructured":"Sun SQ, Kim AH, Cai C, Murphy RK, DeWees T, Sylvester P, Dacey RG, Grubb RL, Rich KM, Zipfel GJ, Dowling JL, Leuthardt EC, Leonard JR, Evans J, Simpson JR, Robinson CG, Perrin RJ, Huang J, Chicoine MR (2014) Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 75(4):347\u2013354. https:\/\/doi.org\/10.1227\/NEU.0000000000000461 (discussion 354\u2013345; quiz 355)","journal-title":"Neurosurgery"},{"issue":"1","key":"399_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1227\/NEU.0000000000001160","volume":"79","author":"SQ Sun","year":"2016","unstructured":"Sun SQ, Cai C, Murphy RK, DeWees T, Dacey RG, Grubb RL, Rich KM, Zipfel GJ, Dowling JL, Leuthardt EC, Simpson JR, Robinson CG, Chicoine MR, Perrin RJ, Huang J, Kim AH (2016) Radiation therapy for residual or recurrent atypical meningioma: the effects of modality, timing, and tumor pathology on long-term outcomes. Neurosurgery 79(1):23\u201332. https:\/\/doi.org\/10.1227\/NEU.0000000000001160","journal-title":"Neurosurgery"},{"issue":"15","key":"399_CR19","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1096\/fasebj.7.15.8262328","volume":"7","author":"WG Stetler-Stevenson","year":"1993","unstructured":"Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr (1993) Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB Jo 7(15):1434\u20131441","journal-title":"FASEB Jo"},{"issue":"4","key":"399_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s007010050112","volume":"140","author":"Y Arai","year":"1998","unstructured":"Arai Y, Kubota T, Nakagawa T, Kabuto M, Sato K, Kobayashi H (1998) Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochir 140(4):377\u2013385 (discussion 385\u2013376)","journal-title":"Acta Neurochir"},{"issue":"5","key":"399_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.prp.2006.01.012","volume":"202","author":"AJ von Randow","year":"2006","unstructured":"von Randow AJ, Schindler S, Tews DS (2006) Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas. Pathol Res Pract 202(5):365\u2013372. https:\/\/doi.org\/10.1016\/j.prp.2006.01.012","journal-title":"Pathol Res Pract"},{"issue":"2","key":"399_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0092-8674(91)90642-C","volume":"64","author":"LA Liotta","year":"1991","unstructured":"Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64(2):327\u2013336","journal-title":"Cell"},{"issue":"1","key":"399_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3171\/jns.1994.81.1.0069","volume":"81","author":"T Nakagawa","year":"1994","unstructured":"Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y (1994) Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 81(1):69\u201377. https:\/\/doi.org\/10.3171\/jns.1994.81.1.0069","journal-title":"J Neurosurg"},{"issue":"4","key":"399_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0092-8674(86)90613-6","volume":"47","author":"P Mignatti","year":"1986","unstructured":"Mignatti P, Robbins E, Rifkin DB (1986) Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47(4):487\u2013498","journal-title":"Cell"},{"issue":"5","key":"399_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3171\/jns.2001.95.5.0839","volume":"95","author":"AC Nordqvist","year":"2001","unstructured":"Nordqvist AC, Smurawa H, Mathiesen T (2001) Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg 95(5):839\u2013844. https:\/\/doi.org\/10.3171\/jns.2001.95.5.0839","journal-title":"J Neurosurg"},{"issue":"5\u20136","key":"399_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0736-5748(99)00010-6","volume":"17","author":"SK Chintala","year":"1999","unstructured":"Chintala SK, Tonn JC, Rao JS (1999) Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 17(5\u20136):495\u2013502","journal-title":"Int J Dev Neurosci"},{"issue":"1\u20133","key":"399_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000468621","volume":"49","author":"P Mignatti","year":"1996","unstructured":"Mignatti P, Rifkin DB (1996) Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49(1\u20133):117\u2013137","journal-title":"Enzyme Protein"},{"issue":"2","key":"399_CR28","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1111\/nan.12166","volume":"41","author":"S Jalali","year":"2015","unstructured":"Jalali S, Singh S, Agnihotri S, Wataya T, Salehi F, Alkins R, Burrell K, Navab R, Croul S, Aldape K, Zadeh G (2015) A role for matrix remodelling proteins in invasive and malignant meningiomas. Neuropathol Appl Neurobiol 41(2):e16-28. https:\/\/doi.org\/10.1111\/nan.12166","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"10","key":"399_CR29","first-page":"7206","volume":"7","author":"T Backer-Grondahl","year":"2014","unstructured":"Backer-Grondahl T, Moen BH, Arnli MB, Torseth K, Torp SH (2014) Immunohistochemical characterization of brain-invasive meningiomas. Int J Clin Exp Pathol 7(10):7206\u20137219","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"399_CR30","doi-asserted-by":"publisher","first-page":"678","DOI":"10.5137\/1019-5149.JTN.12807-14.1","volume":"26","author":"N Karaarslan","year":"2016","unstructured":"Karaarslan N, Gurbuz MS, Caliskan T, Ayan E, Aker FV, Berkman MZ (2016) The effect of matrix metalloproteinase-3 on the prognosis and biological behaviour of meningiomas. Turk Neurosurg 26(5):678\u2013683. https:\/\/doi.org\/10.5137\/1019-5149.JTN.12807-14.1","journal-title":"Turk Neurosurg"},{"issue":"1","key":"399_CR31","first-page":"5","volume":"31","author":"P Tummalapalli","year":"2007","unstructured":"Tummalapalli P, Gondi CS, Dinh DH, Gujrati M, Rao JS (2007) RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol 31(1):5\u201317","journal-title":"Int J Oncol"},{"issue":"5","key":"399_CR32","first-page":"1039","volume":"31","author":"P Tummalapalli","year":"2007","unstructured":"Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH, Rao JS (2007) RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol 31(5):1039\u20131050","journal-title":"Int J Oncol"},{"issue":"9","key":"399_CR33","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00701-003-0097-z","volume":"145","author":"N Levicar","year":"2003","unstructured":"Levicar N, Nuttall RK, Lah TT (2003) Proteases in brain tumour progression. Acta Neurochir 145(9):825\u2013838. https:\/\/doi.org\/10.1007\/s00701-003-0097-z","journal-title":"Acta Neurochir"},{"issue":"1","key":"399_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrm2821","volume":"11","author":"HW Smith","year":"2010","unstructured":"Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11(1):23\u201336. https:\/\/doi.org\/10.1038\/nrm2821","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"399_CR35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nrm977","volume":"3","author":"F Blasi","year":"2002","unstructured":"Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3(12):932\u2013943. https:\/\/doi.org\/10.1038\/nrm977","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"399_CR36","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-03-0545","volume":"10","author":"P Pakneshan","year":"2004","unstructured":"Pakneshan P, Tetu B, Rabbani SA (2004) Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res 10(9):3035\u20133041","journal-title":"Clin Cancer Res"},{"issue":"1","key":"399_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41467-018-03716-9","volume":"9","author":"B Zhang","year":"2018","unstructured":"Zhang B, Zhang Z, Li L, Qin YR, Liu H, Jiang C, Zeng TT, Li MQ, Xie D, Li Y, Guan XY, Zhu YH (2018) TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-kappaB signaling. Nat Commun 9(1):1423. https:\/\/doi.org\/10.1038\/s41467-018-03716-9","journal-title":"Nat Commun"},{"issue":"3\u20134","key":"399_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF01307184","volume":"11","author":"HC Kwaan","year":"1992","unstructured":"Kwaan HC (1992) The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11(3\u20134):291\u2013311","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"399_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1517\/14712598.1.4.683","volume":"1","author":"B Muehlenweg","year":"2001","unstructured":"Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N (2001) Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin Biol Ther 1(4):683\u2013691. https:\/\/doi.org\/10.1517\/14712598.1.4.683","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"399_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF01806809","volume":"40","author":"DF Alonso","year":"1996","unstructured":"Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L, de Kier B, Joffe E (1996) Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 40(3):209\u2013223","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"399_CR41","first-page":"3594","volume":"57","author":"CP Evans","year":"1997","unstructured":"Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA (1997) Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Can Res 57(16):3594\u20133599","journal-title":"Can Res"},{"issue":"3","key":"399_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11060-010-0411-6","volume":"103","author":"JA Kandenwein","year":"2011","unstructured":"Kandenwein JA, Park-Simon TW, Schramm J, Simon M (2011) uPA\/PAI-1 expression and uPA promoter methylation in meningiomas. J Neurooncol 103(3):533\u2013539. https:\/\/doi.org\/10.1007\/s11060-010-0411-6","journal-title":"J Neurooncol"},{"issue":"6","key":"399_CR43","first-page":"1353","volume":"28","author":"S Kondraganti","year":"2006","unstructured":"Kondraganti S, Gondi CS, McCutcheon I, Dinh DH, Gujrati M, Rao JS, Olivero WC (2006) RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol 28(6):1353\u20131360","journal-title":"Int J Oncol"},{"issue":"12","key":"399_CR44","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrc4027","volume":"15","author":"OC Olson","year":"2015","unstructured":"Olson OC, Joyce JA (2015) Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 15(12):712\u2013729. https:\/\/doi.org\/10.1038\/nrc4027","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"399_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1515\/bchm3.1992.373.2.611","volume":"373","author":"M Schmitt","year":"1992","unstructured":"Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L, Graeff H (1992) Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Bio Chem Hoppe-Seyler 373(7):611\u2013622","journal-title":"Bio Chem Hoppe-Seyler"},{"issue":"7","key":"399_CR46","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc1121","volume":"3","author":"JS Rao","year":"2003","unstructured":"Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3(7):489\u2013501. https:\/\/doi.org\/10.1038\/nrc1121","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"399_CR47","first-page":"559","volume":"5","author":"T Strojnik","year":"1999","unstructured":"Strojnik T, Kos J, Zidanik B, Golouh R, Lah T (1999) Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clinical Cancer Res 5(3):559\u2013567","journal-title":"Clinical Cancer Res"},{"issue":"1","key":"399_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/A:1015892911420","volume":"58","author":"N Levicar","year":"2002","unstructured":"Levicar N, Strojnik T, Kos J, Dewey RA, Pilkington GJ, Lah TT (2002) Lysosomal enzymes, cathepsins in brain tumour invasion. J Neurooncol 58(1):21\u201332","journal-title":"J Neurooncol"},{"issue":"41","key":"399_CR49","doi-asserted-by":"publisher","first-page":"E9580","DOI":"10.1073\/pnas.1807751115","volume":"115","author":"JM Reese","year":"2018","unstructured":"Reese JM, Bruinsma ES, Nelson AW, Chernukhin I, Carroll JS, Li Y, Subramaniam M, Suman VJ, Negron V, Monroe DG, Ingle JN, Goetz MP, Hawse JR (2018) ERbeta-mediated induction of cystatins results in suppression of TGFbeta signaling and inhibition of triple-negative breast cancer metastasis. Proc Natl Acad Sci USA 115(41):E9580\u2013E9589. https:\/\/doi.org\/10.1073\/pnas.1807751115","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"399_CR50","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/BF00123393","volume":"14","author":"M Sivaparvathi","year":"1996","unstructured":"Sivaparvathi M, McCutcheon I, Sawaya R, Nicolson GL, Rao JS (1996) Expression of cysteine protease inhibitors in human gliomas and meningiomas. Clin Exp Metas 14(4):344\u2013350","journal-title":"Clin Exp Metas"},{"issue":"5","key":"399_CR51","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3171\/2009.7.JNS081729","volume":"112","author":"TT Lah","year":"2010","unstructured":"Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcevic U, Blejec A, Martin PM (2010) Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg 112(5):940\u2013950. https:\/\/doi.org\/10.3171\/2009.7.JNS081729","journal-title":"J Neurosurg"},{"issue":"1\u20132","key":"399_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/B:GLYC.0000043747.87325.5e","volume":"21","author":"H Habuchi","year":"2004","unstructured":"Habuchi H, Habuchi O, Kimata K (2004) Sulfation pattern in glycosaminoglycan: does it have a code? Glycoconj J 21(1\u20132):47\u201352. https:\/\/doi.org\/10.1023\/B:GLYC.0000043747.87325.5e","journal-title":"Glycoconj J"},{"issue":"2","key":"399_CR53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1172\/JCI13530","volume":"108","author":"JD Esko","year":"2001","unstructured":"Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Investig 108(2):169\u2013173. https:\/\/doi.org\/10.1172\/JCI13530","journal-title":"J Clin Investig"},{"issue":"8","key":"399_CR54","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1158\/1535-7163.MCT-16-0900","volume":"16","author":"A Spyrou","year":"2017","unstructured":"Spyrou A, Kundu S, Haseeb L, Yu D, Olofsson T, Dredge K, Hammond E, Barash U, Vlodavsky I, Forsberg-Nilsson K (2017) Inhibition of heparanase in pediatric brain tumor cells attenuates their proliferation, invasive capacity, and in vivo tumor growth. Mol Cancer Ther 16(8):1705\u20131716. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0900","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"399_CR55","first-page":"60","volume":"31","author":"I Vlodavsky","year":"2001","unstructured":"Vlodavsky I, Goldshmidt O (2001) Properties and function of heparanase in cancer metastasis and angiogenesis. Haemostasis 31(Suppl 1):60\u201363","journal-title":"Haemostasis"},{"issue":"4","key":"399_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1586\/14737175.2.4.459","volume":"2","author":"D Marchetti","year":"2002","unstructured":"Marchetti D (2002) Heparanase: a target for therapy of brain invasive tumors? Expert Rev Neurother 2(4):459\u2013463. https:\/\/doi.org\/10.1586\/14737175.2.4.459","journal-title":"Expert Rev Neurother"},{"key":"399_CR57","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.8b17625","author":"RS Loka","year":"2018","unstructured":"Loka RS, Sletten ET, Barash U, Vlodavsky I, Nguyen HM (2018) Specific inhibition of heparanase by glycopolymer with well-defined sulfation pattern prevents breast cancer metastasis in mice. ACS Appl Mater Interfaces. https:\/\/doi.org\/10.1021\/acsami.8b17625","journal-title":"ACS Appl Mater Interfaces"},{"issue":"12","key":"399_CR58","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/1541-7786.MCR-16-0223","volume":"14","author":"S Kundu","year":"2016","unstructured":"Kundu S, Xiong A, Spyrou A, Wicher G, Marinescu VD, Edqvist PD, Zhang L, Essand M, Dimberg A, Smits A, Ilan N, Vlodavsky I, Li JP, Forsberg-Nilsson K (2016) Heparanase promotes glioma progression and is inversely correlated with patient survival. Mol Cancer Res MCR 14(12):1243\u20131253. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0223","journal-title":"Mol Cancer Res MCR"},{"issue":"10","key":"399_CR59","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1111\/febs.12184","volume":"280","author":"A Meirovitz","year":"2013","unstructured":"Meirovitz A, Goldberg R, Binder A, Rubinstein AM, Hermano E, Elkin M (2013) Heparanase in inflammation and inflammation-associated cancer. FEBS J 280(10):2307\u20132319. https:\/\/doi.org\/10.1111\/febs.12184","journal-title":"FEBS J"},{"issue":"10","key":"399_CR60","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.3324\/haematol.2017.182865","volume":"103","author":"M Galli","year":"2018","unstructured":"Galli M, Chatterjee M, Grasso M, Specchia G, Magen H, Einsele H, Celeghini I, Barbieri P, Paoletti D, Pace S, Sanderson RD, Rambaldi A, Nagler A (2018) Phase I study of the heparanase inhibitor roneparstat: an innovative approach for multiple myeloma therapy. Haematologica 103(10):e469\u2013e472. https:\/\/doi.org\/10.3324\/haematol.2017.182865","journal-title":"Haematologica"},{"issue":"12","key":"399_CR61","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nrm3473","volume":"13","author":"AR Horwitz","year":"2012","unstructured":"Horwitz AR (2012) The origins of the molecular era of adhesion research. Nat Rev Mol Cell Biol 13(12):805\u2013811. https:\/\/doi.org\/10.1038\/nrm3473","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"399_CR62","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1152\/physrev.00014.2011","volume":"92","author":"S Hirano","year":"2012","unstructured":"Hirano S, Takeichi M (2012) Cadherins in brain morphogenesis and wiring. Physiol Rev 92(2):597\u2013634. https:\/\/doi.org\/10.1152\/physrev.00014.2011","journal-title":"Physiol Rev"},{"issue":"4","key":"399_CR63","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1152\/physrev.00004.2017","volume":"97","author":"K Ebnet","year":"2017","unstructured":"Ebnet K (2017) Junctional adhesion molecules (JAMs): cell adhesion receptors with pleiotropic functions in cell physiology and development. Physiol Rev 97(4):1529\u20131554. https:\/\/doi.org\/10.1152\/physrev.00004.2017","journal-title":"Physiol Rev"},{"issue":"6936","key":"399_CR64","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nature01605","volume":"423","author":"BT Marshall","year":"2003","unstructured":"Marshall BT, Long M, Piper JW, Yago T, McEver RP, Zhu C (2003) Direct observation of catch bonds involving cell-adhesion molecules. Nature 423(6936):190\u2013193. https:\/\/doi.org\/10.1038\/nature01605","journal-title":"Nature"},{"issue":"3","key":"399_CR65","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cell.2006.07.020","volume":"126","author":"SK Muthuswamy","year":"2006","unstructured":"Muthuswamy SK (2006) ErbB2 makes beta 4 integrin an accomplice in tumorigenesis. Cell 126(3):443\u2013445. https:\/\/doi.org\/10.1016\/j.cell.2006.07.020","journal-title":"Cell"},{"issue":"6","key":"399_CR66","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nbt0697-542","volume":"15","author":"R Pasqualini","year":"1997","unstructured":"Pasqualini R, Koivunen E, Ruoslahti E (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15(6):542\u2013546. https:\/\/doi.org\/10.1038\/nbt0697-542","journal-title":"Nat Biotechnol"},{"issue":"1","key":"399_CR67","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1038\/s41467-018-07387-4","volume":"9","author":"MC Schmid","year":"2018","unstructured":"Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL, Anand S, Woo G, Leem C, Faridi MH, Geraghty T, Rajagopalan A, Gupta S, Ahmed M, Vazquez-Padron RI, Cheresh DA, Gupta V, Varner JA (2018) Integrin CD11b activation drives anti-tumor innate immunity. Nat Commun 9(1):5379. https:\/\/doi.org\/10.1038\/s41467-018-07387-4","journal-title":"Nat Commun"},{"issue":"5","key":"399_CR68","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/00006123-200011000-00035","volume":"47","author":"L Bello","year":"2000","unstructured":"Bello L, Zhang J, Nikas DC, Strasser JF, Villani RM, Cheresh DA, Carroll RS, Black PM (2000) Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas. Neurosurgery 47(5):1185\u20131195","journal-title":"Neurosurgery"},{"issue":"3","key":"399_CR69","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00701-012-1577-9","volume":"155","author":"F Salehi","year":"2013","unstructured":"Salehi F, Jalali S, Alkins R, Lee JI, Lwu S, Burrell K, Gentili F, Croul S, Zadeh G (2013) Proteins involved in regulating bone invasion in skull base meningiomas. Acta Neurochir 155(3):421\u2013427. https:\/\/doi.org\/10.1007\/s00701-012-1577-9","journal-title":"Acta Neurochir"},{"issue":"1","key":"399_CR70","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1038\/s41467-018-05850-w","volume":"9","author":"F Haun","year":"2018","unstructured":"Haun F, Neumann S, Peintner L, Wieland K, Habicht J, Schwan C, Ostevold K, Koczorowska MM, Biniossek M, Kist M, Busch H, Boerries M, Davis RJ, Maurer U, Schilling O, Aktories K, Borner C (2018) Identification of a novel anoikis signalling pathway using the fungal virulence factor gliotoxin. Nat Commun 9(1):3524. https:\/\/doi.org\/10.1038\/s41467-018-05850-w","journal-title":"Nat Commun"},{"issue":"1","key":"399_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9\u201322. https:\/\/doi.org\/10.1038\/nrc2748","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"399_CR72","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1200\/JCO.2006.06.6514","volume":"25","author":"LB Nabors","year":"2007","unstructured":"Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25(13):1651\u20131657. https:\/\/doi.org\/10.1200\/JCO.2006.06.6514","journal-title":"J Clin Oncol"},{"issue":"1","key":"399_CR73","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11060-016-2094-0","volume":"128","author":"M Khasraw","year":"2016","unstructured":"Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, Kichenadasse G, Ackland S, Wheeler H (2016) Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. J Neurooncol 128(1):163\u2013171. https:\/\/doi.org\/10.1007\/s11060-016-2094-0","journal-title":"J Neurooncol"},{"issue":"5","key":"399_CR74","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/neuonc\/nou356","volume":"17","author":"LB Nabors","year":"2015","unstructured":"Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA (2015) Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol 17(5):708\u2013717. https:\/\/doi.org\/10.1093\/neuonc\/nou356","journal-title":"Neuro Oncol"},{"issue":"10","key":"399_CR75","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M, European Organisation for R, Treatment of C, Canadian Brain Tumor C, team Cs (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u201322072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1100\u20131108. https:\/\/doi.org\/10.1016\/S1470-2045(14)70379-1","journal-title":"Lancet Oncol"},{"issue":"19","key":"399_CR76","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1158\/1078-0432.CCR-12-0299","volume":"19","author":"A Wilisch-Neumann","year":"2013","unstructured":"Wilisch-Neumann A, Kliese N, Pachow D, Schneider T, Warnke JP, Braunsdorf WE, Bohmer FD, Hass P, Pasemann D, Helbing C, Kirches E, Mawrin C (2013) The integrin inhibitor cilengitide affects meningioma cell motility and invasion. Clin Cancer Res 19(19):5402\u20135412. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0299","journal-title":"Clin Cancer Res"},{"issue":"6209","key":"399_CR77","doi-asserted-by":"publisher","first-page":"1254211","DOI":"10.1126\/science.1254211","volume":"346","author":"CD Buckley","year":"2014","unstructured":"Buckley CD, Tan J, Anderson KL, Hanein D, Volkmann N, Weis WI, Nelson WJ, Dunn AR (2014) Cell adhesion. The minimal cadherin-catenin complex binds to actin filaments under force. Science 346(6209):1254211. https:\/\/doi.org\/10.1126\/science.1254211","journal-title":"Science"},{"issue":"6238","key":"399_CR78","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1126\/science.aaa4559","volume":"348","author":"BW Benham-Pyle","year":"2015","unstructured":"Benham-Pyle BW, Pruitt BL, Nelson WJ (2015) Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and beta-catenin activation to drive cell cycle entry. Science 348(6238):1024\u20131027. https:\/\/doi.org\/10.1126\/science.aaa4559","journal-title":"Science"},{"issue":"4","key":"399_CR79","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/15419060802460748","volume":"15","author":"MW Curtis","year":"2008","unstructured":"Curtis MW, Johnson KR, Wheelock MJ (2008) E-cadherin\/catenin complexes are formed cotranslationally in the endoplasmic reticulum\/Golgi compartments. Cell Commun Adhes 15(4):365\u2013378. https:\/\/doi.org\/10.1080\/15419060802460748","journal-title":"Cell Commun Adhes"},{"issue":"5","key":"399_CR80","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1073\/pnas.91.5.1858","volume":"91","author":"T Oda","year":"1994","unstructured":"Oda T, Kanai Y, Oyama T, Yoshiura K, Shimoyama Y, Birchmeier W, Sugimura T, Hirohashi S (1994) E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA 91(5):1858\u20131862","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"399_CR81","doi-asserted-by":"publisher","first-page":"e11231","DOI":"10.1371\/journal.pone.0011231","volume":"5","author":"K Zhou","year":"2010","unstructured":"Zhou K, Wang G, Wang Y, Jin H, Yang S, Liu C (2010) The potential involvement of E-cadherin and beta-catenins in meningioma. PLoS ONE 5(6):e11231. https:\/\/doi.org\/10.1371\/journal.pone.0011231","journal-title":"PLoS ONE"},{"issue":"3","key":"399_CR82","doi-asserted-by":"publisher","first-page":"319","DOI":"10.20892\/j.issn.2095-3941.2017.0024","volume":"14","author":"RA Ahmed","year":"2017","unstructured":"Ahmed RA, Shebl AM, Habashy HO (2017) Expression levels of beta-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study. Cancer Biol Med 14(3):319\u2013326. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2017.0024","journal-title":"Cancer Biol Med"},{"issue":"9","key":"399_CR83","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1182\/blood.V88.9.3259.bloodjournal8893259","volume":"88","author":"GS Kansas","year":"1996","unstructured":"Kansas GS (1996) Selectins and their ligands: current concepts and controversies. Blood 88(9):3259\u20133287","journal-title":"Blood"},{"issue":"1","key":"399_CR84","first-page":"165","volume":"148","author":"KM Schweitzer","year":"1996","unstructured":"Schweitzer KM, Drager AM, van der Valk P, Thijsen SF, Zevenbergen A, Theijsmeijer AP, van der Schoot CE, Langenhuijsen MM (1996) Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol 148(1):165\u2013175","journal-title":"Am J Pathol"},{"issue":"3","key":"399_CR85","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.semcancer.2010.04.005","volume":"20","author":"H Laubli","year":"2010","unstructured":"Laubli H, Borsig L (2010) Selectins promote tumor metastasis. Semin Cancer Biol 20(3):169\u2013177. https:\/\/doi.org\/10.1016\/j.semcancer.2010.04.005","journal-title":"Semin Cancer Biol"},{"issue":"Pt 6","key":"399_CR86","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1042\/BST0321118","volume":"32","author":"A Ivetic","year":"2004","unstructured":"Ivetic A, Ridley AJ (2004) The telling tail of L-selectin. Biochem Soc Trans 32(Pt 6):1118\u20131121. https:\/\/doi.org\/10.1042\/BST0321118","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"399_CR87","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrc1251","volume":"4","author":"MA Hollingsworth","year":"2004","unstructured":"Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45\u201360. https:\/\/doi.org\/10.1038\/nrc1251","journal-title":"Nat Rev Cancer"},{"key":"399_CR88","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.pharmthera.2015.11.005","volume":"157","author":"B Tesfamariam","year":"2016","unstructured":"Tesfamariam B (2016) Involvement of platelets in tumor cell metastasis. Pharmacol Ther 157:112\u2013119. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.11.005","journal-title":"Pharmacol Ther"},{"key":"399_CR89","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clineuro.2017.06.002","volume":"160","author":"P Atukeren","year":"2017","unstructured":"Atukeren P, Turk O, Yanar K, Kemerdere R, Sayyahmelli S, Eren B, Tanriverdi T (2017) Evaluation of ALCAM, PECAM-1 and selectin levels in intracranial meningiomas. Clin Neurol Neurosurg 160:21\u201326. https:\/\/doi.org\/10.1016\/j.clineuro.2017.06.002","journal-title":"Clin Neurol Neurosurg"},{"issue":"7556","key":"399_CR90","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature14407","volume":"522","author":"V Finisguerra","year":"2015","unstructured":"Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, Wauters E, Walmsley S, Prenen H, Granot Z, Casazza A, Mazzone M (2015) MET is required for the recruitment of anti-tumoural neutrophils. Nature 522(7556):349\u2013353. https:\/\/doi.org\/10.1038\/nature14407","journal-title":"Nature"},{"issue":"1","key":"399_CR91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2009.11.005","volume":"16","author":"X Liu","year":"2010","unstructured":"Liu X, Newton RC, Scherle PA (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16(1):37\u201345. https:\/\/doi.org\/10.1016\/j.molmed.2009.11.005","journal-title":"Trends Mol Med"},{"issue":"2","key":"399_CR92","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/JTO.0b013e3182417e44","volume":"7","author":"Y Feng","year":"2012","unstructured":"Feng Y, Thiagarajan PS, Ma PC (2012) MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 7(2):459\u2013467. https:\/\/doi.org\/10.1097\/JTO.0b013e3182417e44","journal-title":"J Thorac Oncol"},{"issue":"2","key":"399_CR93","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3322\/caac.20003","volume":"59","author":"WW Ma","year":"2009","unstructured":"Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59(2):111\u2013137. https:\/\/doi.org\/10.3322\/caac.20003","journal-title":"CA Cancer J Clin"},{"issue":"7408","key":"399_CR94","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500\u2013504. https:\/\/doi.org\/10.1038\/nature11183","journal-title":"Nature"},{"issue":"1","key":"399_CR95","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4132\/jptm.2014.10.13","volume":"49","author":"S Yun","year":"2015","unstructured":"Yun S, Koh JM, Lee KS, Seo AN, Nam KH, Choe G (2015) Expression of c-MET in invasive meningioma. J Pathol Transl Med 49(1):44\u201351. https:\/\/doi.org\/10.4132\/jptm.2014.10.13","journal-title":"J Pathol Transl Med"},{"issue":"9","key":"399_CR96","doi-asserted-by":"publisher","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","volume":"115","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L (2018) Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 Schwannoma models. Proc Natl Acad Sci USA 115(9):E2077\u2013E2084. https:\/\/doi.org\/10.1073\/pnas.1719966115","journal-title":"Proc Natl Acad Sci USA"},{"key":"399_CR97","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/OTT.S40241","volume":"7","author":"RA Parikh","year":"2014","unstructured":"Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ (2014) The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther 7:969\u2013983. https:\/\/doi.org\/10.2147\/OTT.S40241","journal-title":"Onco Targets Ther"},{"issue":"6","key":"399_CR98","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrclinonc.2012.71","volume":"9","author":"S Peters","year":"2012","unstructured":"Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9(6):314\u2013326. https:\/\/doi.org\/10.1038\/nrclinonc.2012.71","journal-title":"Nat Rev Clin Oncol"},{"issue":"42","key":"399_CR99","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1038\/onc.2016.36","volume":"35","author":"V Finisguerra","year":"2016","unstructured":"Finisguerra V, Prenen H, Mazzone M (2016) Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma. Oncogene 35(42):5457\u20135467. https:\/\/doi.org\/10.1038\/onc.2016.36","journal-title":"Oncogene"},{"issue":"3","key":"399_CR100","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cell.2017.11.037","volume":"172","author":"AD Barrow","year":"2018","unstructured":"Barrow AD, Edeling MA, Trifonov V, Luo J, Goyal P, Bohl B, Bando JK, Kim AH, Walker J, Andahazy M, Bugatti M, Melocchi L, Vermi W, Fremont DH, Cox S, Cella M, Schmedt C, Colonna M (2018) Natural killer cells control tumor growth by sensing a growth factor. Cell 172(3):534-548 e519. https:\/\/doi.org\/10.1016\/j.cell.2017.11.037","journal-title":"Cell"},{"issue":"2","key":"399_CR101","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","volume":"157","author":"S Weissmueller","year":"2014","unstructured":"Weissmueller S, Manchado E, Saborowski M, Morris JPT, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, Grimmond SM, Pilarsky C, Prives C, Biankin AV, Lowe SW (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 157(2):382\u2013394. https:\/\/doi.org\/10.1016\/j.cell.2014.01.066","journal-title":"Cell"},{"issue":"3","key":"399_CR102","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2013.12.029","volume":"156","author":"K Leder","year":"2014","unstructured":"Leder K, Pitter K, LaPlant Q, Hambardzumyan D, Ross BD, Chan TA, Holland EC, Michor F (2014) Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell 156(3):603\u2013616. https:\/\/doi.org\/10.1016\/j.cell.2013.12.029","journal-title":"Cell"},{"issue":"4","key":"399_CR103","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/2018.1.FOCUS17754","volume":"44","author":"S Gupta","year":"2018","unstructured":"Gupta S, Bi WL, Dunn IF (2018) Medical management of meningioma in the era of precision medicine. Neurosurg Focus 44(4):E3. https:\/\/doi.org\/10.3171\/2018.1.FOCUS17754","journal-title":"Neurosurg Focus"},{"key":"399_CR104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2016.12.004","volume":"73","author":"M Tuchen","year":"2017","unstructured":"Tuchen M, Wilisch-Neumann A, Daniel EA, Baldauf L, Pachow D, Scholz J, Angenstein F, Stork O, Kirches E, Mawrin C (2017) Receptor tyrosine kinase inhibition by regorafenib\/sorafenib inhibits growth and invasion of meningioma cells. Eur J Cancer 73:9\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.004","journal-title":"Eur J Cancer"},{"issue":"4","key":"399_CR105","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jocn.2014.10.030","volume":"22","author":"MD Johnson","year":"2015","unstructured":"Johnson MD, Reeder JE, O\u2019Connell M (2015) MKP-3 regulates PDGF-BB effects and MAPK activation in meningioma cells. J Clin Neurosci 22(4):752\u2013757. https:\/\/doi.org\/10.1016\/j.jocn.2014.10.030","journal-title":"J Clin Neurosci"},{"issue":"4","key":"399_CR106","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clineuro.2010.12.007","volume":"113","author":"GA Alexiou","year":"2011","unstructured":"Alexiou GA, Markoula S, Gogou P, Kyritsis AP (2011) Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 113(4):261\u2013267. https:\/\/doi.org\/10.1016\/j.clineuro.2010.12.007","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"399_CR107","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3171\/jns.1997.87.2.0315","volume":"87","author":"RS Carroll","year":"1997","unstructured":"Carroll RS, Black PM, Zhang J, Kirsch M, Percec I, Lau N, Guha A (1997) Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 87(2):315\u2013323. https:\/\/doi.org\/10.3171\/jns.1997.87.2.0315","journal-title":"J Neurosurg"},{"issue":"12","key":"399_CR108","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/01.jnen.0000189834.63951.81","volume":"64","author":"M Johnson","year":"2005","unstructured":"Johnson M, Toms S (2005) Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol 64(12):1029\u20131036","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"399_CR109","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00401-004-0875-6","volume":"108","author":"U Andersson","year":"2004","unstructured":"Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, Henriksson R (2004) Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108(2):135\u2013142. https:\/\/doi.org\/10.1007\/s00401-004-0875-6","journal-title":"Acta Neuropathol"},{"issue":"1","key":"399_CR110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00280-004-0780-7","volume":"54","author":"R Katayama","year":"2004","unstructured":"Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH, Vail DM (2004) Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 54(1):25\u201333. https:\/\/doi.org\/10.1007\/s00280-004-0780-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"399_CR111","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.leu.2403247","volume":"18","author":"R Aloyz","year":"2004","unstructured":"Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L (2004) Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18(3):409\u2013414. https:\/\/doi.org\/10.1038\/sj.leu.2403247","journal-title":"Leukemia"},{"issue":"4","key":"399_CR112","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-004-0913-z","volume":"55","author":"T O'Reilly","year":"2005","unstructured":"O\u2019Reilly T, Wartmann M, Maira SM, Hattenberger M, Vaxelaire J, Muller M, Ferretti S, Buchdunger E, Altmann KH, McSheehy PMJ (2005) Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 55(4):307\u2013317. https:\/\/doi.org\/10.1007\/s00280-004-0913-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"399_CR113","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00280-015-2927-0","volume":"77","author":"E Mazza","year":"2016","unstructured":"Mazza E, Brandes A, Zanon S, Eoli M, Lombardi G, Faedi M, Franceschi E, Reni M (2016) Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 77(1):115\u2013120. https:\/\/doi.org\/10.1007\/s00280-015-2927-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"399_CR114","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","volume":"139","author":"DS Osorio","year":"2018","unstructured":"Osorio DS, Hu J, Mitchell C, Allen JC, Stanek J, Hagiwara M, Karajannis MA (2018) Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neurooncol 139(3):749\u2013755. https:\/\/doi.org\/10.1007\/s11060-018-2922-5","journal-title":"J Neurooncol"},{"issue":"2","key":"399_CR115","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","volume":"96","author":"AD Norden","year":"2010","unstructured":"Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211\u2013217. https:\/\/doi.org\/10.1007\/s11060-009-9948-7","journal-title":"J Neurooncol"},{"issue":"4","key":"399_CR116","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/jnen\/63.4.275","volume":"63","author":"K Lamszus","year":"2004","unstructured":"Lamszus K (2004) Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63(4):275\u2013286","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9","key":"399_CR117","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.14670\/HH-28.1157","volume":"28","author":"P Baumgarten","year":"2013","unstructured":"Baumgarten P, Brokinkel B, Zinke J, Zachskorn C, Ebel H, Albert FK, Stummer W, Plate KH, Harter PN, Hasselblatt M, Mittelbronn M (2013) Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol Histopathol 28(9):1157\u20131166. https:\/\/doi.org\/10.14670\/HH-28.1157","journal-title":"Histol Histopathol"},{"issue":"3","key":"399_CR118","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11060-004-9164-4","volume":"70","author":"S Otsuka","year":"2004","unstructured":"Otsuka S, Tamiya T, Ono Y, Michiue H, Kurozumi K, Daido S, Kambara H, Date I, Ohmoto T (2004) The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neurooncol 70(3):349\u2013357","journal-title":"J Neurooncol"},{"issue":"4","key":"399_CR119","first-page":"938","volume":"46","author":"K Lamszus","year":"2000","unstructured":"Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergun S, Westphal M (2000) Vascular endothelial growth factor, hepatocyte growth factor\/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46(4):938\u2013947 (discussion 947\u2013938)","journal-title":"Neurosurgery"},{"issue":"1","key":"399_CR120","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ncponc0403","volume":"3","author":"RK Jain","year":"2006","unstructured":"Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3(1):24\u201340. https:\/\/doi.org\/10.1038\/ncponc0403","journal-title":"Nat Clin Pract Oncol"},{"issue":"21","key":"399_CR121","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMc1403303","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Sulman EP, Mehta MP (2014) Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(21):2048\u20132049. https:\/\/doi.org\/10.1056\/NEJMc1403303","journal-title":"N Engl J Med"},{"key":"399_CR122","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1559292","author":"CA Dasanu","year":"2018","unstructured":"Dasanu CA, Alvarez-Argote J, Limonadi FM, Codreanu I (2018) Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs. Expert Opin Biol Ther. https:\/\/doi.org\/10.1080\/14712598.2019.1559292","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"399_CR123","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nou148","volume":"17","author":"TJ Kaley","year":"2015","unstructured":"Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A (2015) Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 17(1):116\u2013121. https:\/\/doi.org\/10.1093\/neuonc\/nou148","journal-title":"Neuro Oncol"},{"issue":"8","key":"399_CR124","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"3","key":"399_CR125","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","volume":"130","author":"SJ Han","year":"2016","unstructured":"Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H (2016) Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol 130(3):543\u2013552. https:\/\/doi.org\/10.1007\/s11060-016-2256-0","journal-title":"J Neurooncol"},{"issue":"3","key":"399_CR126","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/14737175.2018.1429920","volume":"18","author":"C Apra","year":"2018","unstructured":"Apra C, Peyre M, Kalamarides M (2018) Current treatment options for meningioma. Expert Rev Neurother 18(3):241\u2013249. https:\/\/doi.org\/10.1080\/14737175.2018.1429920","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"399_CR127","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/cmt.6.4.285.292","volume":"6","author":"M Wahab","year":"2003","unstructured":"Wahab M, Al-Azzawi F (2003) Meningioma and hormonal influences. Climacteric 6(4):285\u2013292","journal-title":"Climacteric"},{"issue":"2","key":"399_CR128","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1200\/JCO.2007.14.2133","volume":"26","author":"S Blitshteyn","year":"2008","unstructured":"Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 26(2):279\u2013282. https:\/\/doi.org\/10.1200\/JCO.2007.14.2133","journal-title":"J Clin Oncol"},{"key":"399_CR129","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-16-0054","author":"T O'Shea","year":"2016","unstructured":"O\u2019Shea T, Crowley RK, Farrell M, MacNally S, Govender P, Feeney J, Gibney J, Sherlock M (2016) Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/EDM-16-0054","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"10","key":"399_CR130","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1002\/ijc.29274","volume":"136","author":"VS Benson","year":"2015","unstructured":"Benson VS, Kirichek O, Beral V, Green J (2015) Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 136(10):2369\u20132377. https:\/\/doi.org\/10.1002\/ijc.29274","journal-title":"Int J Cancer"},{"key":"399_CR131","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13138","author":"X Shu","year":"2019","unstructured":"Shu X, Jiang Y, Wen T, Lu S, Yao L, Meng F (2019) Association of hormone replacement therapy with increased risk of meningioma in women: a hospital-based multicenter study with propensity score matching. Asia Pac J Clin Oncol. https:\/\/doi.org\/10.1111\/ajco.13138","journal-title":"Asia Pac J Clin Oncol"},{"issue":"12","key":"399_CR132","doi-asserted-by":"publisher","first-page":"e83261","DOI":"10.1371\/journal.pone.0083261","volume":"8","author":"ZY Qi","year":"2013","unstructured":"Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z (2013) Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS ONE 8(12):e83261. https:\/\/doi.org\/10.1371\/journal.pone.0083261","journal-title":"PLoS ONE"},{"key":"399_CR133","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-00569-x","author":"T Deli","year":"2019","unstructured":"Deli T, Orosz M, Jakab A (2019) Hormone replacement therapy in cancer survivors\u2014review of the literature. Pathol Oncol Res. https:\/\/doi.org\/10.1007\/s12253-018-00569-x","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"399_CR134","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/07357900601062339","volume":"24","author":"SM Grunberg","year":"2006","unstructured":"Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24(8):727\u2013733. https:\/\/doi.org\/10.1080\/07357900601062339","journal-title":"Cancer Invest"},{"issue":"34","key":"399_CR135","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","volume":"33","author":"Y Ji","year":"2015","unstructured":"Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C (2015) Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol 33(34):4093\u20134098. https:\/\/doi.org\/10.1200\/JCO.2015.61.6490","journal-title":"J Clin Oncol"},{"issue":"3","key":"399_CR136","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00701-018-03782-4","volume":"161","author":"PO Champagne","year":"2019","unstructured":"Champagne PO, Passeri T, Froelich S (2019) Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report. Acta Neurochir 161(3):589\u2013592. https:\/\/doi.org\/10.1007\/s00701-018-03782-4","journal-title":"Acta Neurochir"},{"issue":"4","key":"399_CR137","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3171\/2013.12.JNS131170","volume":"120","author":"JM Schildkraut","year":"2014","unstructured":"Schildkraut JM, Calvocoressi L, Wang F, Wrensch M, Bondy ML, Wiemels JL, Claus EB (2014) Endogenous and exogenous hormone exposure and the risk of meningioma in men. J Neurosurg 120(4):820\u2013826. https:\/\/doi.org\/10.3171\/2013.12.JNS131170","journal-title":"J Neurosurg"},{"issue":"1","key":"399_CR138","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3171\/jns.1999.91.1.0093","volume":"91","author":"KE Friend","year":"1999","unstructured":"Friend KE, Radinsky R, McCutcheon IE (1999) Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 91(1):93\u201399. https:\/\/doi.org\/10.3171\/jns.1999.91.1.0093","journal-title":"J Neurosurg"},{"issue":"3","key":"399_CR139","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3171\/jns.2001.94.3.0487","volume":"94","author":"IE McCutcheon","year":"2001","unstructured":"McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE (2001) Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94(3):487\u2013492. https:\/\/doi.org\/10.3171\/jns.2001.94.3.0487","journal-title":"J Neurosurg"},{"issue":"9","key":"399_CR140","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/labinvest.3700307","volume":"85","author":"S Puttmann","year":"2005","unstructured":"Puttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH, Paulus W (2005) Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest 85(9):1163\u20131171. https:\/\/doi.org\/10.1038\/labinvest.3700307","journal-title":"Lab Invest"},{"issue":"2","key":"399_CR141","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11060-005-9076-y","volume":"78","author":"GS Baia","year":"2006","unstructured":"Baia GS, Slocum AL, Hyer JD, Misra A, Sehati N, VandenBerg SR, Feuerstein BG, Deen DF, McDermott MW, Lal A (2006) A genetic strategy to overcome the senescence of primary meningioma cell cultures. J Neurooncol 78(2):113\u2013121. https:\/\/doi.org\/10.1007\/s11060-005-9076-y","journal-title":"J Neurooncol"},{"issue":"3","key":"399_CR142","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.surneu.2007.06.031","volume":"70","author":"BT Ragel","year":"2008","unstructured":"Ragel BT, Couldwell WT, Gillespie DL, Wendland MM, Whang K, Jensen RL (2008) A comparison of the cell lines used in meningioma research. Surg Neurol 70(3):295\u2013307. https:\/\/doi.org\/10.1016\/j.surneu.2007.06.031","journal-title":"Surg Neurol"},{"issue":"2","key":"399_CR143","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3171\/JNS\/2008\/108\/2\/0304","volume":"108","author":"BT Ragel","year":"2008","unstructured":"Ragel BT, Elam IL, Gillespie DL, Flynn JR, Kelly DA, Mabey D, Feng H, Couldwell WT, Jensen RL (2008) A novel model of intracranial meningioma in mice using luciferase-expressing meningioma cells. Laboratory investigation. J Neurosurg 108(2):304\u2013310. https:\/\/doi.org\/10.3171\/JNS\/2008\/108\/2\/0304","journal-title":"J Neurosurg"},{"issue":"1","key":"399_CR144","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cell.2011.03.026","volume":"145","author":"DA Haber","year":"2011","unstructured":"Haber DA, Gray NS, Baselga J (2011) The evolving war on cancer. Cell 145(1):19\u201324. https:\/\/doi.org\/10.1016\/j.cell.2011.03.026","journal-title":"Cell"},{"issue":"2","key":"399_CR145","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","volume":"129","author":"KC Shih","year":"2016","unstructured":"Shih KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, Shepard GC, Williams JT, Shastry M, Burris HA 3rd, Hainsworth JD (2016) A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 129(2):281\u2013288. https:\/\/doi.org\/10.1007\/s11060-016-2172-3","journal-title":"J Neurooncol"},{"key":"399_CR146","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.wneu.2015.09.060","volume":"86","author":"M Karsy","year":"2016","unstructured":"Karsy M, Hoang N, Barth T, Burt L, Dunson W, Gillespie DL, Jensen RL (2016) Combined hydroxyurea and verapamil in the clinical treatment of refractory meningioma: human and orthotopic xenograft studies. World Neurosurg 86:210\u2013219. https:\/\/doi.org\/10.1016\/j.wneu.2015.09.060","journal-title":"World Neurosurg"},{"issue":"2","key":"399_CR147","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2967\/jnumed.114.147256","volume":"56","author":"N Marincek","year":"2015","unstructured":"Marincek N, Radojewski P, Dumont RA, Brunner P, Muller-Brand J, Maecke HR, Briel M, Walter MA (2015) Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med 56(2):171\u2013176. https:\/\/doi.org\/10.2967\/jnumed.114.147256","journal-title":"J Nucl Med"},{"issue":"3","key":"399_CR148","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/neuonc\/nov183","volume":"18","author":"J Furtner","year":"2016","unstructured":"Furtner J, Schopf V, Seystahl K, Le Rhun E, Ruda R, Roelcke U, Koeppen S, Berghoff AS, Marosi C, Clement P, Faedi M, Watts C, Wick W, Soffietti R, Weller M, Preusser M (2016) Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro Oncol 18(3):401\u2013407. https:\/\/doi.org\/10.1093\/neuonc\/nov183","journal-title":"Neuro Oncol"},{"issue":"3","key":"399_CR149","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","volume":"84","author":"AD Norden","year":"2015","unstructured":"Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY (2015) Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 84(3):280\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000001153","journal-title":"Neurology"},{"issue":"11","key":"399_CR150","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","volume":"56","author":"K Gerster-Gillieron","year":"2015","unstructured":"Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D (2015) 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med 56(11):1748\u20131751. https:\/\/doi.org\/10.2967\/jnumed.115.155853","journal-title":"J Nucl Med"},{"issue":"5","key":"399_CR151","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00280-014-2422-z","volume":"73","author":"M Simo","year":"2014","unstructured":"Simo M, Argyriou AA, Macia M, Plans G, Majos C, Vidal N, Gil M, Bruna J (2014) Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol 73(5):919\u2013923. https:\/\/doi.org\/10.1007\/s00280-014-2422-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"399_CR152","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","volume":"117","author":"JJ Raizer","year":"2014","unstructured":"Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, Rice L, McCarthy K, Johnston SK, Mrugala MM, Chamberlain M (2014) A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol 117(1):93\u2013101. https:\/\/doi.org\/10.1007\/s11060-014-1358-9","journal-title":"J Neurooncol"},{"issue":"2","key":"399_CR153","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","volume":"106","author":"DA Reardon","year":"2012","unstructured":"Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS (2012) Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 106(2):409\u2013415. https:\/\/doi.org\/10.1007\/s11060-011-0687-1","journal-title":"J Neurooncol"},{"issue":"1","key":"399_CR154","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","volume":"109","author":"L Nayak","year":"2012","unstructured":"Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109(1):187\u2013193. https:\/\/doi.org\/10.1007\/s11060-012-0886-4","journal-title":"J Neurooncol"},{"issue":"1","key":"399_CR155","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","volume":"109","author":"E Lou","year":"2012","unstructured":"Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE 2nd, McSherry F, Norfleet J, Friedman HS, Reardon DA (2012) Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series. J Neurooncol 109(1):63\u201370. https:\/\/doi.org\/10.1007\/s11060-012-0861-0","journal-title":"J Neurooncol"},{"issue":"5","key":"399_CR156","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/neuonc\/nor044","volume":"13","author":"DR Johnson","year":"2011","unstructured":"Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC (2011) Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol 13(5):530\u2013535. https:\/\/doi.org\/10.1093\/neuonc\/nor044","journal-title":"Neuro Oncol"},{"issue":"6","key":"399_CR157","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1215\/15228517-2009-010","volume":"11","author":"PY Wen","year":"2009","unstructured":"Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01\u201308). Neuro Oncol 11(6):853\u2013860. https:\/\/doi.org\/10.1215\/15228517-2009-010","journal-title":"Neuro Oncol"},{"issue":"9","key":"399_CR158","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","volume":"36","author":"M Bartolomei","year":"2009","unstructured":"Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Arico D, Sansovini M, Paganelli G (2009) Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36(9):1407\u20131416. https:\/\/doi.org\/10.1007\/s00259-009-1115-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"399_CR159","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cncr.23803","volume":"113","author":"MC Chamberlain","year":"2008","unstructured":"Chamberlain MC, Glantz MJ (2008) Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113(8):2146\u20132151. https:\/\/doi.org\/10.1002\/cncr.23803","journal-title":"Cancer"},{"issue":"10","key":"399_CR160","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","volume":"69","author":"MC Chamberlain","year":"2007","unstructured":"Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69(10):969\u2013973. https:\/\/doi.org\/10.1212\/01.wnl.0000271382.62776.b7","journal-title":"Neurology"},{"issue":"4","key":"399_CR161","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0028-3770(04)98326-9","volume":"50","author":"S Fuentes","year":"2004","unstructured":"Fuentes S, Chinot O, Dufour H, Paz-Paredes A, Metellus P, Barrie-Attarian M, Grisoli F (2004) Hydroxyurea treatment for unresectable meningioma. Neurochirurgie 50(4):461\u2013467","journal-title":"Neurochirurgie"},{"issue":"1\u20132","key":"399_CR162","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","volume":"67","author":"D Loven","year":"2004","unstructured":"Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A (2004) Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67(1\u20132):221\u2013226","journal-title":"J Neurooncol"},{"issue":"7","key":"399_CR163","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","volume":"62","author":"MC Chamberlain","year":"2004","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62(7):1210\u20131212","journal-title":"Neurology"},{"issue":"2","key":"399_CR164","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3171\/jns.2002.97.2.0341","volume":"97","author":"WP Mason","year":"2002","unstructured":"Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97(2):341\u2013346. https:\/\/doi.org\/10.3171\/jns.2002.97.2.0341","journal-title":"J Neurosurg"},{"issue":"8","key":"399_CR165","first-page":"2269","volume":"7","author":"C Muhr","year":"2001","unstructured":"Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B (2001) Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 7(8):2269\u20132276","journal-title":"Clin Cancer Res"},{"issue":"5","key":"399_CR166","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3171\/jns.1997.86.5.0840","volume":"86","author":"UM Schrell","year":"1997","unstructured":"Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86(5):840\u2013844. https:\/\/doi.org\/10.3171\/jns.1997.86.5.0840","journal-title":"J Neurosurg"},{"issue":"2","key":"399_CR167","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00006123-199702000-00007","volume":"40","author":"SE Kaba","year":"1997","unstructured":"Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung WK (1997) The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40(2):271\u2013275","journal-title":"Neurosurgery"},{"issue":"1","key":"399_CR168","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF01050266","volume":"15","author":"JW Goodwin","year":"1993","unstructured":"Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15(1):75\u201377","journal-title":"J Neurooncol"}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-021-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10014-021-00399-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-021-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T03:35:30Z","timestamp":1627443330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10014-021-00399-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":168,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s10014-021-00399-x","relation":{},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"14 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}